Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic HER2-positive breast cancer previously treated with a HER2-directed regimen in the metastatic setting, or recurring during or within six months after neoadjuvant or adjuvant HER2-directed treatment.
LAMPGEN ANALYSIS
Why it matters
This traditional approval also broadened eligibility to an earlier line or early recurrence after curative-intent treatment.
What research teams should watch
Verify the HER2 result and the timing and setting of prior HER2 therapy. Include pulmonary symptom triage in monitoring.
PRIMARY RECORDS